{"id":"W2948884915","doi":"10.1038/s41591-019-0476-5","title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":326,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health; Nature","keywords":"Medicine; Dabrafenib; Melanoma; Trametinib; Pembrolizumab; MEK inhibitor; Immunotherapy; Discontinuation; Blockade; Internal medicine; Oncology; Adverse effect; Combination therapy; Targeted therapy; MAPK/ERK pathway; Vemurafenib; Immunology; Pharmacology; Cancer research; Cancer; Kinase; Metastatic melanoma; Biology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001855429,0.0001747786,0.0002400927,0.00008048589,0.00002743876,0.000006757976,0.00008104361,0.0003232635,0.00007144124],"category_scores_gemma":[0.00003015291,0.0001199872,0.00002208429,0.0001247407,0.0000832571,0.00000432307,0.00003228992,0.0003051044,0.000006008216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001216733,"about_ca_system_score_gemma":0.00004090485,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003282883,"about_ca_topic_score_gemma":0.00007699897,"domain_scores_codex":[0.999082,0.00004224757,0.000176571,0.0003277577,0.0001698331,0.0002015405],"domain_scores_gemma":[0.9995309,0.00001538638,0.00006917084,0.0002718589,0.00004714176,0.00006551688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004770285,0.00004251824,0.01161036,0.00003238181,0.00003094706,0.00003802577,0.0001355893,0.000001299959,0.9855612,0.0003427294,0.0004655044,0.001262443],"study_design_scores_gemma":[0.01414676,0.005704735,0.07601328,0.0003089034,0.00002966909,0.0002544421,0.0002525736,0.00004681145,0.8693783,0.0003063181,0.03312759,0.0004305818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922408,0.003322185,0.00004728528,0.001247916,0.0002009618,0.0003193176,0.000007167115,0.00001340058,0.002600932],"genre_scores_gemma":[0.9972904,0.0002791233,0.0001257514,0.001344347,0.0002173055,0.0000111544,0.0001692161,0.00002277393,0.0005398668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1161828,"threshold_uncertainty_score":0.4892937,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.002431315230869503,"score_gpt":0.2083139023884205,"score_spread":0.205882587157551,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}